Table 1.
Clinical Outcomes for Patients Treated with Allogeneic CAR Therapies.
| CAR Type | Total number of Patients | Patients with r/r DLBCL | Acute GVHD | Chronic GVHD | Overall Efficacy (BOR) | Efficacy in r/r DLBCL (BOR) | T-cell Chimerism | Costimulatory Domain | Transduction Type |
|---|---|---|---|---|---|---|---|---|---|
| Axi-cel from allo-HCT donor (20) | 7 | 7 | 3 (43%) | 0 (0%) | 3 CR, 1 PR (57%) | Same as overall | 100% in 4/7, NR for others | CD28 | Retrovirus |
| UCB-derived CAR-NK (21) | 11 | 2 | 0 (0%) | 0 (0%) | 7 CR, 1 PR (73%) | 1 CR (50%) | N/A | CD28 | Retrovirus |
| EBV-CTL (41 )(NCT01430390) | 10 | 1 | 1 (10%) | 0 (0%) | 7 CR (70%) | 1 CR (100%) | NR | CD28 | Retrovirus |
| Allo-HCT donor-derived CAR (16) | 20 | 5 | 0 (0%) | 2 (10%) | 6 CR, 2 PR (40%) | 1 CR, 3 SD (80%) | NR | CD28 | Retrovirus |
| Allo-HCT donor-derived CAR (17) | 19 | 2 | 2 (11%) | 1 (5%) | 11 CR (58%) | 1 CR (50%) | NR | CD28 | Sleeping Beauty transposon/transposase |
| Allo-HCT recipient-derived CAR (18) | 21 | 1 | 0 (0%) | 0 (0%) | 3 CR (14%) | 1 PD (0%) | NR | CD28 | Retrovirus |
Allo-HCT, allogeneic hematopoietic cell transplant; Axi-cel, axicabtagene ciloleucel; BOR, best overall response; CAR, chimeric antigen receptor; CR, complete remission; DLI, donor leukocyte infusion; EBV-CTL, EBV-specific cytotoxic lymphocytes; GVHD, graft-versus-host disease; NR, not reported; N/A, not available; PR, partial remission; r/r DLBCL, relapsed/refractory diffuse large B-cell lymphoma; SD, stable disease; UCB, umbilical cord blood.